Filing Flows › Opus Genetics (IRD) › Stock forecast & fair value
Opus Genetics (IRD) stock forecast and price target
Opus Genetics (IRD) trades at $4.18. 17 analysts' median price target is $13.00 (+211%), from $8.00 to $20.00.
Opus Genetics' latest quarter
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IRD stock?
The median of 17 analysts' 12-month targets is $13.00, +211% from $4.18; the range is $8.00 to $20.00. The average rating is none.
Does Opus Genetics usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is IRD stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.